All news

Fresenius signs largest biosimilars deal for up to 37 candidates

Investing.com · · AI-summarised by FinFlash

Fresenius signed an exclusive development agreement with WuXi Biologics giving it option rights over up to 37 biosimilar candidates over the next decade, potentially expanding its portfolio from 29 to as many as 66 molecules addressing more than EUR 370 billion in originator sales. It holds global commercialisation rights and pays per selected candidate from operating cash flow. It kept 2026 guidance, and Reuters said it expects to raise long-term Biopharma ambitions.

So What?

The pact could lift Fresenius's Biopharma growth without new financing and marks a sizable win for WuXi. Watch both stocks and any revision to long-term targets.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.